drugset / Trial / NCT06147063
A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to characterize the safety and immunogenicity of AZD9838 and AZD6563 when administered as a single dose vaccination against SARS-CoV-2 in adults.
Timeline
- Start
- 2023-11-27
- Primary completion
- 2024-04-30
- Completion
- 2025-03-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD6563 | Vaccine | — | Intramuscular |
| Subject | AZD9838 | Vaccine | — | Intramuscular |
| Comparator | Licensed mRNA vaccine | Messenger RNA (mRNA) | — | Intramuscular |